Therapeutic trials with HPA23, alpha-IFN and ribavirin in AIDS patients.
D000386:AIDS-Related Complex / Q000188:drug therapy*; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000628:therapy*; D000965:Antimony / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D012254:Ribavirin / Q000627:therapeutic use*; D012263:Ribonucleosides / Q000627:therapeutic use*; D014414:Tungsten / Q000627:therapeutic use*; D017973:Tungsten Compounds
D000998:Antiviral Agents; D007370:Interferon Type I; D012263:Ribonucleosides; D017973:Tungsten Compounds; D012254:Ribavirin; C009613:ammonium tungsten antimonate hydroxide oxide; D000965:Antimony; D014414:Tungsten